Date: 2011-04-04
Type of information: R&D agreement
Compound: novel chemical compounds that inhibit the activity of a novel protein target, proposed by IPD
Company: Selvita (Poland) The Institutes for Pharmaceutical Discovery (USA)
Therapeutic area: undisclosed
Type agreement: R&D
Action mechanism:
Disease: undisclosed
Details: Selvita, Poland based integrated discovery partner for the pharmaceutical and biotechnology industry, announced today an agreement with the Institutes for Pharmaceutical Discovery (IPD) in Branford, CT, USA to provide computational chemistry services to IPD. The aim of this agreement is to identify novel chemical compounds that inhibit the activity of a novel protein target, proposed by IPD. This target protein was selected as the result of a collaboration between IPD and an academic institution, and may be linked to an important class of human diseases. The compounds identified during this project are expected to demonstrate therapeutic potential as a result of their interaction with the selected protein target. The results of the computational analysis will be experimentally tested in drug discovery research conducted by IPD. The scope of the project, commissioned to Selvita, includes a druggability study of the targeted protein, followed by a virtual high-throughput screen of structures attainable in public databases, and the interpretation of the “lead-likeness” of the proposed compounds.
Financial terms:
Latest news:
